June 4, 2020 / 1:50 PM / a month ago

BRIEF-Genmab Announces European Marketing Authorization For Subcutaneous Formulation Of Darzalex®

June 4 (Reuters) - Genmab A/S:

* REG-GENMAB ANNOUNCES EUROPEAN MARKETING AUTHORIZATION FOR THE SUBCUTANEOUS FORMULATION OF DARZALEX® (DARATUMUMAB) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

* APPROVAL APPLIES TO ALL CURRENT DARATUMUMAB INDICATIONS IN FRONTLINE AND RELAPSED/REFRACTORY SETTINGS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below